New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection, Rev Med Virol, vol.17, issue.5, pp.355-63, 2007. ,
Fetal cytomegalovirus infection, Best Pract Res Clin Obstet Gynaecol. janv, vol.38, pp.97-107, 2017. ,
In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study, Am J Obstet Gynecol, vol.215, issue.4, pp.462-463, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02641581
Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999, Birth Defects Res A Clin Mol Teratol. avr, vol.70, issue.4, pp.201-208, 2004. ,
Contributions of the ex vivo human perfused placenta in the study of placental transfer of drugs, J Gyné cologie Obstétrique Biol Reprod. dé c, vol.39, issue.8, pp.601-606, 2010. ,
Criteria for evaluating perfusion experiments and presentation of results, Contrib Gynecol Obstet, vol.13, pp.32-41, 1985. ,
Transfer across the perfused human placenta of antipyrine, sodium and leucine, Am J Obstet Gynecol, vol.15, issue.6, p.4676572, 1972. ,
, PREVYMIS (letermovir) Tablets and PREVYMIS (letermovir) Injection
Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment, Br J Clin Pharmacol. sept, vol.83, issue.9, pp.1944-53, 2017. ,
Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infection and Drug Resistance, 2015. ,
, Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246, vol.54, pp.1290-1297, 20047911.
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation, N Engl J Med, vol.21, issue.25, pp.2433-2477, 2017. ,
Update on New Antivirals Under Development for the Treatment of Double-Stranded DNA Virus Infections, Clin Pharmacol Ther, vol.88, issue.5, pp.610-619, 2010. ,
Preclinical and Toxicology Studies of 1263W94, a Potent and Selective Inhibitor of Human Cytomegalovirus Replication, Antimicrob Agents Chemother. 8 janv, vol.46, issue.8, pp.2373-80, 2002. ,
, Efficacy and Safety Study of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir -Full Text View-ClinicalTrials
, Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients-Full Text View-ClinicalTrials, p.19
Placental transfer of drugs, Therapie. fé vr, vol.69, issue.1, pp.3-11, 2014. ,
Placental transfer and metabolism: An overview of the experimental models utilizing human placental tissue, Toxicol In Vitro [Internet]. fé vr, vol.27, issue.1, pp.507-519, 2013. ,
Placental Transfer of Rilpivirine in an Ex Vivo Human Cotyledon Perfusion Model, Antimicrob Agents Chemother. 5 janv, vol.59, issue.5, pp.2901-2904, 2015. ,
Placental transfer of lopinavir/ ritonavir in the ex vivo human cotyledon perfusion model, Am J Obstet Gynecol. juill, vol.195, issue.1, pp.296-301, 2006. ,
Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model, AIDS Lond Engl. 28 janv, vol.32, issue.3, pp.321-326, 2018. ,
Rivaroxaban transfer across the dually perfused isolated human placental cotyledon, Am J Obstet Gynecol, vol.213, issue.5, pp.710-711, 2015. ,
Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs, Br J Obstet Gynaecol. sept, vol.91, issue.9, p.6477846, 1984. ,
Fetal hepatic drug elimination, Pharmacol Ther. dé c, vol.84, issue.3, pp.46-53, 1999. ,
, Fetal Pharmacotherapy. Drugs. 1 avr, vol.62, issue.5, pp.757-73, 2002.
Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model, Antimicrob Agents Chemother. 1 mai, vol.60, issue.5, pp.3112-3116, 2016. ,
Placental transfer of darunavir in an ex vivo human cotyledon perfusion model, Antimicrob Agents Chemother. sept, vol.58, issue.9, pp.5617-5637, 2014. ,
Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model, Am J Obstet Gynecol. 1 janv, vol.206, issue.1, pp.92-93, 2012. ,
, CRAT-Centre de ré fé rence sur les agents tératogènes chez la femme enceinte
Quality assessment of a placental perfusion protocol, Reprod Toxicol. 1 aoû t, vol.30, issue.1, pp.138-184, 2010. ,
Placental perfusion: interest and limits, J Matern Fetal Neonatal Med. 3 juin, vol.30, issue.11, pp.1347-1355, 2017. ,